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1. Introduction
The administration of macromolecular 
drugs such as protein- or peptide-based 
drugs by conventional routes suffers from 
certain challenges. Some of the impor-
tant challenges faced by these biomole-
cules are their large size, hydrophilicity, 
short biological half-life, poor membrane 
permeability, phagocytic clearance, and 
structural instability.[1,2] They also undergo 
degradation in biological compartments, 
which leads to low bioavailability.[3] In 
order to circumvent these challenges, 
many strategies have been adopted for the 
delivery of hydrophilic macromole cules. 
Amongst which the nanotechnology-
enabled delivery systems have offered 
great promise due to small size and 
sustained release properties.[4–6] In the 
nanoparticles-based delivery systems for 
peptidal drugs, the drug is entrapped, 
encapsulated, or attached to the nano-
particle matrix, depending upon the prep-
aration method.[7] The submicron size of 
these nanoparticles is a critical parameter 
in the enhanced cellular uptake in con-
trast to micro-carrier delivery systems.[8,9] 
However, since these delivery systems are 
mostly based on hydrophobic polymers the hydrophobic envi-
ronment may induce unfolding of protein-based drugs and 
nucleotide drugs, that consequently may result in diminished 
biological activity.[10–12] Moreover, the nanoparticles based on 
these hydrophobic biodegradable polymers have also demon-
strated poor loading potential for hydrophilic drug molecules[13] 
and thus backbone modification was investigated.[14,15] In con-
trast to that, hydrophilic biopolymers which are obtained from 
living organisms have been found as a promising material 
for nanosystems to deliver hydrophilic macromolecules. This 
is also due to their biodegradability and excellent biocompat-
ibility.[6,16,17] Amongst these, gelatin is one of the most versatile 
biomacromolecular polymers which has been predominantly 
used in foods,[18,19] cosmetics,[20] pharmaceuticals,[21,22] and 
medical applications.[23] It is a natural water soluble proteina-
ceous biomaterial obtained by base- or acid-catalyzed hydrolysis 
of collagen. Accordingly, there are two types of gelatins. Type A 
gelatin is produced as a result of acidic hydrolysis of collagen 
with an isoelectric point (IEP) between 7 and 9.[24] Type B 
Surface Crosslinking
For nanotechnology enabled delivery of hydrophilic protein-based drugs, 
several polymer-based carrier systems have been used in the past to protect 
the sensitive load and to facilitate cellular uptake and crossing of biological 
barriers. This study uses gelatin, a natural and biodegradable macromolecule, 
as carrier material which is approved for several applications. Nanoprecipi-
tation is used to form nanoparticles and to maintain the physicochemical 
integrity of gelatin, hydrophilic crosslinkers, e.g., paraformaldehyde, glutaral-
dehyde, carbodiimide, and transglutaminase are employed. However, these 
crosslinkers diffuse homogenously into the carrier matrix also crosslinking 
the polymeric matrix with the entrapped protein-based molecules thus 
rendering it inactive. Hence a hydrophobic zero-length crosslinker, diiso-
propylcarbodiimide, is applied to avoid diffusion into the particles. This will 
provide an opportunity to encapsulate protein-based drugs in the non-
crosslinked matrix. The hypothesis of surface crosslinking is proven by the 
extent of crosslinking and more importantly by encapsulation and the release 
of lysozyme as a model hydrophilic protein. Furthermore, essential process 
parameters are evaluated such as crosslinker concentration, crosslinking 
time and crosslinking reaction temperature with regard to the effect on 
particle size, size distribution and zeta-potential of gelatin nanoparticles. The 
optimum formulation results in the production of gelatin nanoparticles with 
200-300 nm and a polydispersity index < 0.2.
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gelatin is obtained by alkaline hydrolysis of collagen with IEP 
between 4.8 and 5.2.[25] It is an excipient mostly regarded as 
safe (GRAS) which is approved by the FDA for pharmaceutical 
applications such as plasma expanders (Gelafusal, Gelafundin) 
based on derivatives of gelatin.[26] It is an interesting biomate-
rial possessing several characteristics, for example, a) inexpen-
sive, b) non-pyrogenic, and c) low antigenicity.[27,28] Due to its 
protein nature, it possesses several functionalities, such as car-
boxyl, amino, phenol, guanidine, and imidazole groups, which 
offer potential sites for conjugation or chemical modification. 
Due to these characteristic features, gelatin has been frequently 
reported in the literature as controlled release biomaterial for 
biologically active substances.[29] The delivery systems fabri-
cated from gelatin include hydrogels,[30] microspheres,[31] scaf-
folds,[32] and nanoparticles.[33]
Hydrophilicity is one of the important physicochemical 
properties of gelatin due to which it is well-suited for the 
incorporation of hydrophilic macromolecular drugs. But, 
from formulation point of view, gelatin-based drug delivery 
systems cannot maintain their structural integrity upon expo-
sure to aqueous environment thus disassembling and imme-
diately releasing the incorporated payload.[34] Hence, it is 
important to stabilize these gelatin-based carrier systems in 
order to achieve physicochemical and mechanical stabilization 
in aqueous environment. Ever since the discovery of gelatin 
nano particles (GNPs) by Oppenheim et al.,[35] crosslinking has 
been an indispensable step for the preparation of stable GNPs. 
For this purpose, different crosslinkers have been used so far 
such as glutaraldehyde (GTA),[36] glyoxal,[37] genipin,[38] water 
soluble carbodiimide,[39] microbial transglutaminases,[40] and 
reduced sugars.[41] However, these crosslinkers crosslink the 
carrier matrix and also the loaded protein drug. The drug will 
not be released and might also be not active after crosslinking. 
Therefore, a novel strategy for the stabilization of GNPs is 
needed.[34]
In this study, we intend to crosslink GNPs only on the 
interface using hydrophobic zero-length crosslinkers in order 
to avoid the diffusion of crosslinker inside the nanoparticle 
matrix. To the best of our knowledge, the stabilization of GNPs 
with the application of hydrophobic zero-length crosslinkers is 
not reported so far. The aim of this study is to design nano-
sized hydrophilic gel-based particles for the delivery of hydro-
philic macromolecules. The subsequent stabilization of 
the loaded GNPs with hydrophobic crosslinker will overcome 
the main drawback for flexible protein delivery. For the selective 
interfacial crosslinking of GNPs, we employed diisopropylcar-
bodiimide (DIC).
2. Results and Discussion
2.1. Preparation of DIC-Crosslinked GNPs
This research work aimed to introduce a novel formulation 
strategy for the physicochemical stabilization of GNPs, using 
the zero-length hydrophobic crosslinker, DIC. We hypothesize 
that the hydrophobic crosslinker due to its low polarity (hydro-
phobicity) might be confined in the external environment 
(i.e., anti-solvent phase, acetone in our case) and would not 
diffuse into the hydrophilic matrix of GNPs. Consequently, 
only the amino acid and carboxylic acid functionalities located 
on the colloidal interface will be coupled together thus estab-
lishing an amide crosslink on the surface of the nano particles. 
The formation of GNPs was carried out following the 
standard protocols of nanoprecipitation.[42] Briefly, the solvent 
phase (aqueous solution of gelatin) is added dropwise to the 
anti-solvent (acetone) containing stabilizer.[36,43] Due to diffu-
sion of the solvent phase into the anti-solvent phase, a strong 
interfacial turbulence is produced which leads to precipitation 
of gelatin at the interface in the form of GNPs.[42,44,45] Sub-
sequently, the crosslinker DIC was added to the nanosuspen-
sion followed by stirring for 24 h to favor crosslink formation 
on GNPs. The preparation procedure is shown schematically 
in Figure 1.
Macromol. Chem.  Phys. 2019, 220, 1900260
Figure 1. Schematic representation of the procedure to form GNPs via nanoprecipitation and surface crosslinking the particles by DIC.
www.advancedsciencenews.com www.mcp-journal.de
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1900260 (3 of 12)
2.2. Optimization of Crosslinker Concentration
Type B gelatin with bloom number 75 was used throughout 
the experiments which contains approximately 33 × 10−5 moles 
ε-amino groups per gram on the lysine and hydroxy-lysine 
residues, and approximately 126 × 10−5 moles carboxylic acid 
groups per gram on glutamic and aspartic acids.[46] The hydro-
philic nature of gelatin requires the physicochemical stabili-
zation via crosslinking. The hydrophobic crosslinker (DIC) 
activates the carboxylic moiety present in a peptide network 
forming an activated O-acylisourea which is subsequently 
attacked by a nucleophile present in another peptide chain, for 
example, primary amino groups, forming a stable amide bond 
which acts as intra- and inter-peptide crosslinks (Figure 2). The 
obtained GNPs when crosslinked with crosslinkers in concen-
tration ranges from 0.99 to 3.98 mg mL−1 display a mean size 
of 250 nm with a broad size distribution [polydispersity index 
(PDI) > 0.2] (Figure 3). Monodisperse nanosuspensions were 
obtained for DIC concentration ≥  4.98 mg mL−1 (5–15 mg 
mL−1) revealing an optimum stability in aqueous environment. 
These crosslinker concentrations from 4.98 to 15 mg mL−1 have 
no influence on particle size (Figure 3).
The crosslinking was performed over 20–24 h but 
crosslinking time was also found to have an impact on particle 
stabilization. Therefore, the effect of crosslinking time on the 
mean size and the size distribution was studied.
2.3. Optimum Crosslinking Time
2.3.1. Effect of DIC Concentration and Crosslinking Temperature
Using the crosslinker with two concentrations, 5 and 
15 mg mL−1 at room temperature, resulted in optimal phys-
icochemical stability in aqueous environment after 25–30 and 
15–20 h, respectively. No agglomeration of the particles was 
observed. The mean sizes of crosslinked GNPs at these con-
ditions were found to be 241.80 nm for a crosslinker concen-
tration of 5 mg mL−1, and 231.72 nm for 15 mg mL−1, both 
formulations showed a PDI < 0.2 after 48 or 20 h, respectively. 
Hence, increasing the crosslinker concentration to 15 mg mL−1 
reduced the optimum crosslinking time (Table 1). The whole 
dataset measured can be seen in Figures S1 and S2, Supporting 
Information.
Since the endothermic chemical reaction kinetics were 
increased with increase in temperature, the DIC-induced 
crosslinking process should also be activated. The crosslinking 
reaction was performed at two temperature levels, 30 °C and 
Macromol. Chem.  Phys. 2019, 220, 1900260
Figure 2. Schematic representation of DIC-mediated crosslinking mechanism. A) Formation of DIC-mediated activation of (–COOH) to form the 
unstable intermediate O-Acylisourea; and B) secondary reaction with nucleophilic substitution of free primary amino groups presented by lysine into 
the formerly formed DIC activated ester leading to formation of amide crosslink at GNPs interface.
Figure 3. Effect of crosslinker concentration (DIC) on particle size and 
size distribution. The nanoparticles were measured in water after tenfold 
dilution before purification in three independent experiments (n = 3).
Table 1. Summary of the impact of crosslinker concentration and tem-
perature of crosslinking mixture on the optimum crosslinking time nec-
essary for the stability of particles in aqueous environment. The mean 
sizes and size distribution of crosslinked nanoparticles at corresponding 









size ± SD [nm]
Mean  
PDI ± SD
5 23 48 241.80 ± 30.07 0.16 ± 0.08
5 30 25 252.92 ± 16.80 0.14 ± 0.05
5 50 5 250.54 ± 11.53 0.11 ± 0.07
15 23 15 231.72 ± 4.29 0.15 ± 0.02
15 30 3 253.55 ± 9.21 0.13 ± 0.02
15 50 2 269.45 ± 9.21 0.16 ± 0.03
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50 °C in an incubator using the previously used crosslinker 
concentrations. It was observed that the optimum crosslinking 
time is inversely related to temperature as expected. For a DIC 
concentration of 5 mg mL−1 the crosslinking time could be 
shortened to 25 h at 30 °C and 5 h at 50 °C. Consequently, for 
the higher crosslinker concentration the time could be short-
ened even further to 3 h at 30 °C and 2 h at 50 °C. Hence, it 
can be inferred that temperature has a direct impact on stabi-
lization kinetics mediated by chemical crosslinking with DIC. 
Performing the crosslinking of GNPs suspension with DIC at 
higher temperatures led to a reduction in the optimum incuba-
tion time which is necessary for the physicochemical stability of 
GNPs in aqueous environments.
However, for all formulations, the mean particle size 
increased at higher temperatures. Thus, in combination with 
the possible encapsulation of temperature sensitive proteins, 
we decided to use a concentration of 15 mg mL−1 DIC and 
crosslink the particles at room temperature for 18 h to achieve 
a stable formulation.
2.4. Investigation of DIC-Mediated Crosslinkability of Gelatin 
Nanoparticles
2.4.1. Quantification of Crosslinking Degree—TNBS Assay
The crosslinking degree of DIC-induced crosslinked GNPs 
was quantitatively determined by trinitro benzenesulfonic acid 
(TNBS) assay.[47] TNBS assay is based on spectrophotometric 
determination of primary amino groups in crosslinked and 
uncrosslinked particles. TNBS reacts with the primary amino 
groups under mild alkaline conditions to produce an unstable 
Meisenheimer complex followed by acidification which con-
verts the unstable intermediate complex to a pale-yellow stable 
trinitrophenyl derivative, which can be quantified spectrophoto-
metrically at λmax = 349 nm.
Based on the absorbance of uncrosslinked and crosslinked 
GNPs, the total number of primary amino groups engaged in 
crosslinking GNPs was calculated. The result demonstrated 
that the crosslinking degree in GNPs after 18 h of crosslinking 
is proportional to the crosslinker concentration until a plateau 
is reached (Figure 4). The plateau starts from around 3.98 mg 
mL−1. This is also supported by a statistical analysis using a 
one-way ANOVA analysis which states that the corresponding 
crosslinking degrees for DIC concentrations from 3.98 up to 
18.4 mg mL−1 were statistically insignificant. Hence increasing 
the quantity of crosslinker has no influence on the percentage 
of the crosslinking extent within the errors of the measure-
ment. This demonstrates a saturation of the crosslinking 
process. Thus, there are no more free primary amino groups 
which can be reached for crosslinking.
In another experiment, the crosslinking time was extended 
to 48 h and subsequently the crosslinking degrees were deter-
mined (Figure 5). According to statistical analysis (one-way 
ANOVA, p > 0.05), we see that the difference of the measured 
crosslinking degrees were not statistically significant. There-
fore, for 48 h crosslinking the degree of crosslinking is not 
influenced by the concentration of crosslinker anymore. The 
maximum crosslinking degree found was ≈25–30%. This low 
amount of crosslinking might be attributed to the hydrophobic 
nature of the crosslinker. Due to this property of DIC, diffu-
sion into the polar core is limited. Therefore, the uncrosslinked 
amino groups should be localized in the interior of nano-
particles not being exposed to the crosslinker. Consequently, 
a crosslinker-free core area should be obtained. This is also 
supported by the fact that stable nanoparticles can be pre-
pared. If crosslinking would not be on the outside of the par-
ticles the uncrosslinked part should be dissolved not forming 
particulates.
Based on the results of the TNBS assay we can calculate the 
potential architecture assuming that all crosslinked groups 
are on the outside, whereas the core is not crosslinked at all. 
Furthermore, assuming a homogeneous distribution of the 
crosslinkable groups we can estimate the crosslinked versus 
the non-crosslinked volume resulting in a core–shell structure 
with an inner sphere of radius Runcrosslinked sphere = 111 nm and a 
crosslinked edge of 14 nm thickness (Figure 6).
Macromol. Chem.  Phys. 2019, 220, 1900260
Figure 4. Relationship between % crosslinking extent and concentrations 
of crosslinker (DIC) in mg mL−1 for 18 h crosslinking time. The volumes 
were kept constant during the preparations. Values determined from 
TNBS assay by using the absorption maximum of λmax = 349 nm, n = 3. 
N.S., statistically non-significant on the basis of p > 0.05 as per one-way 
ANOVA. *, statistically significant, p < 0.05 as per one-way ANOVA.
Figure 5. Relationship between % crosslinking degree and amount of 
crosslinker (mg mL−1) for 48 h crosslinking reaction time. Values deter-
mined by TNBS assay using an absorption maximum of λmax = 349 nm, 
n = 3. NS, statistically non-significant on the basis of p > 0.05 as per 
one-way ANOVA.
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2.4.2. Monitoring of Crosslinker after Crosslinking Reaction
Quantification of Unreacted Crosslinker—Gas Chromatography: 
The unreacted crosslinker (DIC) was determined quantitatively 
using a pre-established gas chromatography method using a 
flame ionization detector (GC-FID). The calibration curve was 
constructed after plotting concentrations of different calibra-
tion standards of DIC in acetone versus corresponding peak 
areas under each GC chromatogram. For this investigation 
of the formulations, three GNP formulations with different 
crosslinker amounts were considered. Afterward, these GNP 
colloidal dispersions were centrifuged at 20 000 × g for 25 min. 
The supernatant was extracted and analyzed for the amount 
of unreacted crosslinker present in each formulation of GNP 
suspension.
From the experimental data in Table 2 one could conclude 
that the converted masses of DIC are the same for all experi-
ments irrespective of the initial amount of crosslinker used. As 
the mass of gelatin and thus the number of particles and the 
available surface is constant within the error of the experiment, 
this behavior is well in line with the TNBS assay. Only a certain 
amount of crosslinker is being consumed in the crosslinking 
process of GNPs indicating that we have a saturatable pro-
cess (Table 2, Figures 4 and 5). Moreover, the total amount of 
crosslinker utilized in the crosslinking process is extremely low. 
Presumably, due to hydrophobicity, the crosslinker (DIC) has 
only accessibility to the functional groups present at the col-
loidal interface of GNPs, and is not diffusing into the interior 
of the GNPs. Hence, when all the available reactive groups pre-
sent on the interface are crosslinked, no further crosslinking 
takes place.
Quantification of Diisopropylurea: A Crosslinking By-Product 
As elaborated above (Figure 2), DIC conjugates the carboxylate 
groups with the primary amino groups present in the gelatin 
peptide network forming an amide bond which is responsible 
for the physicochemical and mechanical integrity of GNPs 
in aqueous environment. Consequently, DIC is transformed 
into its corresponding by-product known as diisopropylurea 
(DIU) which is soluble for instance in acetone but insoluble 
in aqueous solutions. The DIU was quantified using 1H NMR 
spectroscopy. The amount of DIU in the GNPs suspension was 
obtained after centrifuging DIC-crosslinked GNPs (24 000 × g, 
for 30 min). Afterward, the supernatant consisting of a mixture 
of crosslinker (DIC) and DIU dissolved in acetone was analyzed 
with 1H NMR spectroscopy.
The proton NMR spectrum of the crosslinking mixtures 
showed resonances for DIU together with tiny signals for the 
by-product DIU providing the methyl resonances for quanti-
fication (Figure S3A, Supporting Information). In contrast to 
DIC the methyl protons of DIU were slightly shifted to higher 
field appearing almost free of superimposition in the region of 
the high field carbon-13 satellite of the DIC methyl resonances 
(Figure S3A, Supporting Information, close-up). Therefore, 
integration of the separate DIU methyl doublet lines as well 
as the DIC methyl carbon-13 satellite lines could easily be per-
formed (Figure S3B, Supporting Information). These integra-
tion values were taken to establish the relationship between the 
amount of DIC and DIU, taking into account that a carbon-13 
satellite resonance represented only 0.55% of the complete 
peak intensity. This way of quantification provided much more 
accurate results than a direct integration of the methyl reso-
nances of the main compound DIC. The calculation can be 
seen in Equation (S1).
Looking at the 1H NMR-based quantification of DIU 
found in the sample (Figure 7), it is evident that during the 
crosslinking process of GNPs mediated by DIC, the by-
product (DIU) is formed in extremely low amounts. With a 
fixed mass of gelatin (20 mg), the amount of DIU formed after 
Macromol. Chem.  Phys. 2019, 220, 1900260
Figure 6. Estimated geometry of DIC-crosslinked GNP based on TNBS assay. V(sphere), total volume of GNP sphere; V(internal sphere), volume of non-
crosslinked sphere; V(crosslinked), volume of crosslinked part of GNP; R(uncrosslinked sphere), radius of uncrosslinked part of GNP which is the interior of 
GNP; R(sphere), total radius of GNP; D(crosslinked), sum of the thickness of the crosslinked edge (nm).
Table 2. Relationship between crosslinker amounts (mg) used initially 
for crosslinking and amounts of DIC consumed in crosslinking of GNPs.
Amount added initially 
[mg]
Unreacted amount  
[mg] ± SD
Reacted amounta)  
[mg] ± SD
32.4 26.36 ± 3.03 6.04 ± 3.03
48.6 44.40 ± 0.21 4.20 ± 0.21
64.8 57.38 ± 0.01 6.97 ± 0.01
a)The reacted amounts were found statistically insignificant on the basis of p > 0.05 
as per one-way ANOVA.
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crosslinking reaction is independent of whatever amount of 
DIC is being used.
Thus, from NMR and GC data, it can be also concluded that 
crosslinking of a certain number of available amino and car-
boxylic groups took place but no further crosslinking. Hence, 
the TNBS assay, gas chromatography, and 1H NMR data sup-
port the surface-restricted crosslinking behavior of hydrophobic 
crosslinker DIC and the simple core–shell model derived.
2.5. Zeta Potential of DIC-Crosslinked GNPs
The zeta potential of DIC-crosslinked GNPs purified via tangen-
tial flow filtration (TFF) was measured at different pH values. 
Since gelatin is a polyamphoteric biopolymer possessing both 
anionic and cationic functional groups, the overall charge of 
gelatin backbone is dependent on the pH of the surrounding. 
Since type B gelatin possesses relatively high proportion of 
acidic amino groups like aspartate and glutamate as compared 
to basic amino groups (e.g., lysine, hydroxy-lysine, arginine) 
low IEP (4–5) is the consequence.
It is evident from the zeta potential profile (Figure 8) that 
the GNPs possess slightly positive zeta potential (between +11 
and +7 mV) at pH 5 and 6, respectively. For pH larger than 
7, the zeta potential is shifting to negative values. At neutral 
pH 7, the zeta potential is almost zero. The zeta potential 
of GNPs suspension is expected to be zero at the isoelectric 
pH of type B gelatin (pH 4.7–5.4). However, a shift of the 
IEP of gelatin toward 6–7 (Figure 8) is observed. This phe-
nomenon can be associated to the DIC crosslinking and its 
crosslinking mechanism. Gelatin contains twice as much argi-
nine (5%) than l-lysine (2.7%).[48,49] Assuming that all lysine 
residues are engaged in crosslinking leaves free arginin which 
is not involved in crosslinking. The pKa value of arginine is 
found to be 12.1 leading to a shift to higher pH values.[50] In 
consequence to this shift of IEP to higher pH values, the zeta 
potential of DIC-crosslinked GNPs is close to neutral for neu-
tral pH.
2.6. Morphological Characterization–Scanning Electron 
Microscopy
The scanning electron microscopy (SEM) analysis of DIC-
crosslinked GNPs revealed that the nanoparticles have spher-
ical morphology (Figure 9). The mean size calculated from 
SEM image using imageJ is summarized in Table 3. As can 
Macromol. Chem.  Phys. 2019, 220, 1900260
Figure 7. Quantification of the reaction by-product DIU. The diagram shows the results of the DIU quantification, calculated by the integral of the 
corresponding peaks for different amounts of crosslinker. Negative control: sample without gelatin. * p < 0.05 as per one-way ANOVA, NS, statistically 
non-significant.
Figure 8. Zeta potential of type B GNPs crosslinked with DIC 15 mg mL−1 
measured at different pH values after TFF-based purification.
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be seen, the mean size of GNPs determined by SEM micro-
graph is lower than that of DLS analysis. Presumably, this is 
due to drying of samples before SEM imaging in contrast to the 
hydrated particles in aqueous dispersion.[42,51]
2.7. Drug Loading and Release
Lysozyme in different mass ratios of drug to polymer was added 
to the gelatin solution used for GNPs preparation. Afterward 
the GNPs were subsequently crosslinked with DIC for 48 h 
(the optimum crosslinking time for lysozyme-loaded GNPs). 
The drug to polymer mass ratios included 2.5%, 5%, 10%, 
25%, and 50%. The mean size of loaded GNPs (Table 4) did 
not change compared to the unloaded GNPs within the range 
of 2.5–5% ratio of lysozyme to gelatin (i.e., 170–190 nm). For 
higher amounts of loaded lysozyme (loading ratio of 5–25%) 
the size increased by 20–30 nm. However, all particle formu-
lations showed a narrow size distribution (Table 4). Loading 
lysozyme above 25% led to visible aggregate formation hence 
unstable nanosuspensions. Thus, the maximum loading ratio 
of lysozyme to gelatin was found to be 25%.
The zeta potential values of lysozyme-loaded GNPs was 
observed to be highly positive at neutral pH as compared to 
unloaded GNPs possessing slightly negative zeta potential at 
neutral pH (Table 4). The positive zeta potential of lysozyme-
loaded GNPs could be attributed to the successful loading of 
the lysozyme molecules which are positively charged at these 
conditions.
The entrapment efficiency is above 80% for all amounts of 
lysozyme leading to stable nanosuspensions. The loading is 
constantly increasing and can be adjusted up to 12%. The in 
vitro release profile of lysozyme loaded GNPs from the gelatin 
matrix, demonstrated that about 40% of lysozyme was released 
in the initial 0.5 h (Figure 10). This fast burst release has also 
been reported by other investigators.[52] The burst release of 
approximately 40–50% was followed by a sustained release up 
to an extent of 90–100% for 24 h. Lysozyme is a cationic poly-
peptide composed of 129 amino acids containing many basic as 
well as acidic amino acid residues[53] thus providing a favorable 
environment for crosslinking reaction by crosslinker (e.g., 
DIC). Nevertheless, the maximum release up to 90–100% of 
lysozyme from DIC-mediated crosslinked GNPs matrix reveals 
that the crosslinker is only slightly involved in crosslinking 
the payload allowing high fraction of release. In contrast, the 
Macromol. Chem.  Phys. 2019, 220, 1900260
Figure 9. SEM micrographs of DIC-crosslinked GNPs purified via ultra-filtration using tangential flow filtration performed with a regenerated cellulose 
membrane of 100 kDa pore size. A) Concentrated sample. B) Diluted sample.
Table 4. Physicochemical properties of unloaded and lysozyme-loaded GNPs. DLS measurements were performed in acetone.
Used lysozyme [% m/m of gelatin] Size ± SD [nm] PDI ± SD Zeta potential at pH 7 [mV] Entrapment efficiency ± SD [%] Loading efficiency ± SD [%]
Unloaded GNPs 184.19 ± 5.20 0.09 ± 0.05 −4.43 ± 2.30 — —
2.5 178.84 ± 10.26 0.07 ± 0.01 10.66 ± 2.30 99.60 ± 3.35 3.35 ± 1.33
5 184.76 ± 7.20 0.08 ± 0.02 10.57 ± 0.76 87.01 ± 4.79 4.79 ± 1.16
10 205.00 ± 10.00 0.09 ± 0.02 28.14 ± 0.97 93.97 ± 9.87 9.87 ± 1.71
25 221.25 ± 7.00 0.07 ± 0.02 — 80.92 ± 12.20 12.20 ± 5.11
30 ND ND ND ND ND
40 ND ND ND ND ND
50 ND ND ND ND ND
ND, not determined due to visible precipitate formation.
Table 3. Size characterization of DIC-crosslinked GNPs purified via 
tangential flow filtration (TFF).




TFF filtration (RCc 
membrane of 100 kDa)
224.5 ± 1.87 (0.12) 145.33 ± 58.12
a)Term in parenthesis represent PDI; b)100 particles analyzed using imageJ 
software. RCc, regenerated cellulose.
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release from the standard GNP stabilized by GTA crosslinking 
showed a maximum of only 30% release of lysozyme while 70% 
is not available for release. As GTA is a hydrophilic homobi-
functional crosslinker which also diffused into the core of the 
nano-particulate matrix also crosslinking the drug load.
2.8. Determination of Biological Activity
To determine the biological activity of lysozyme after particle 
crosslinking either with DIC, or with GTA, a Micrococcus lyso-
deikticus assay was used. The particles were incubated with 
the gem for 24 h and the activity was measured as described. 
DIC-GNPs were crosslinked for 48 h, as described before. The 
crosslinking time for GTA-GNPs was reduced from 48 to 24 h, 
as under this condition stable particles could be prepared and, 
due to the lower crosslinking degree, more protein might be 
uncrosslinked and active.
The activity-based determined amounts of lysozyme, that 
is, turbidimetric bioassay, were compared with HPLC-based 
determined amounts. The released samples from crosslinked 
GNPs in PBS (pH 7.4) following incubation for 24 h at 37 °C 
with continuous shaking at 400 rpm were analyzed using both 
assays simultaneously. The results are depicted for both types 
of GNP systems in Table 5.
The analysis of the released amount clearly indicates that 
more lysozyme can be released from the DIC-crosslinked 
system compared to the GTA-crosslinked system as already 
seen in Section 2.7. Looking at the turbidimetric assay it is 
evident that during the formation of loaded GNPs and subse-
quently crosslinking with DIC, the biological activity of encap-
sulated lysozyme is preserved. For both types of particles, only 
a small fraction of 11% is released and seems not to be active 
anymore (difference between the released amount and the 
active amount). Notably, the enzymatic activity of lysozyme 
released from GTA-crosslinked GNPs is clearly lower than the 
activity of the amount released from the surface-crosslinked 
DIC particles.
The lower activity and correspondingly the low released 
extent of lysozyme in the case of GTA-crosslinked GNPs 
can be attributed to inter-molecular crosslinking (gelatin–
lysozyme). In contrast, the higher activity and correspond-
ingly, the higher release extent of lysozyme from DIC-
crosslinked GNPs matrices is a clear indication that the 
hydrophobic crosslinker (DIC) is involved to a lower extent 
in the inter-molecular conjugation between lysozyme and 
the carrier molecule (gelatin). After comparing the release 
data of GTA-GNPs crosslinked for 24 h with the release data 
of GTA-GNPs crosslinked for 48 h (see Figure 10), it is evi-
dent that the release extent of lysozyme is higher than the 
release shown in Figure 10 due to shorter crosslinking time. 
But, it is also notable that although the release is high, the 
related activity is much lower. This supports our hypothesis 
as for longer crosslinking, the release and the corresponding 
activity would be even lower.
Therefore, it can be inferred that the intended therapeutic 
activity of encapsulated peptide-based cargo is not interfered fol-




Gelatin type B Bloom 75 from bovine skin, pluronic F-68 
(Poloxamer 188) and DIC (reagent grade) were purchased 
from Sigma-Aldrich (Steinheim, Germany). Hen-egg-white 
lysozyme and GTA aqueous solution (25% w/w, grade II) was 
purchased from Sigma-Aldrich, Steinheim, Germany. The 
lyophilized powder consisting of M. lysodeikticus ATCC 4698 
cells as a substrate for lysozyme was purchased from Sigma-
Aldrich, Steinheim, Germany. Acetone was obtained from 
Fischer Chemicals Ltd., (Loughborough, UK). Milli-Q water 
with a resistivity of 18.2 MΩ cm−1was used throughout the 
experiments. TFF cassettes fitted with modified regenerated 
cellulose material (Hydrosart) with an MWCO of 100 kDa was 
purchased from Sartorius Stedim Biotech Ltd. (Göttingen, 
Germany).
3.2. Nanoparticle Fabrication by Nanoprecipitation
GNPs were fabricated using the established formulation recipe 
based on the nanoprecipitation technique.[42] Briefly, the solvent 
Macromol. Chem.  Phys. 2019, 220, 1900260
Figure 10. In vitro release profile of DIC- and GTA-crosslinked gelatin 
nanoparticles loaded with lysozyme in phosphate buffer saline (PBS) pH 
7.4 as release medium at 37 °C. N.S., non-significant statistically on the 
basis of p > 0.05 using one-way ANOVA.
Table 5. Comparison between lysozyme amounts analyzed via turbidi-




Activity [%] Release [%] Activity [%] Release [%]
24 36.67 ± 4.26 48.11 ± 2.83 84.42 ± 8.18 95.15 ± 7.15
The data is an average of three independent experiments (n = 3); a)Crosslinking 
time: 24 h; b)Crosslinking time: 48 h.
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phase was prepared by dissolving 20 mg of gelatin in 1 mL 
of deionized water at 50 °C. Afterward, the solvent phase was 
added dropwise to the anti-solvent phase consisting of ace-
tone containing Poloxamer 188 (3% w/v). Subsequently, the 
GNPs were crosslinked with varying amounts of DIC solution 
in acetone from its stock solution (69.16% w/v) for varying 
crosslinking time intervals. Finally, the crude nanosuspen-
sion was purified using ultra-filtration in TFF mode to remove 
the unreacted crosslinker (DIC), its by-products and excess 
amounts of stabilizers (Poloxamer 188). Nanoparticles were 
washed using TFF before morphological characterization. To 
measure the colloidal properties during the optimization pro-
cess, GNPs without purification were analyzed by dynamic 
light scattering (DLS).
3.2.1. Formulation Optimization
In order to demonstrate an optimum stability in aqueous envi-
ronment, the GNPs should be sufficiently crosslinked. In this 
connection, various parameters such as crosslinker concen-
tration, crosslinking time (incubation time), and crosslinking 
reaction temperature were investigated for their influence on 
particle size, size distribution, and zeta potential.
Influence of the Crosslinker Concentration: The crude suspen-
sion of GNPs was allowed to react with varying concentrations 
of DIC (0.99–15 mg mL−1) to investigate its possible impact 
on mean particle size and size distribution. The gelatin con-
centration in the solvent phase was 20 mg mL−1, the solvent/
non-solvent ratio was 1:15, and the stabilizer concentration was 
3% w/v.
Influence of the Crosslinking Time: In order to investigate 
the minimum crosslinking reaction time, the nanosuspen-
sion was allowed to react with the crosslinker at different 
crosslinking incubation times (0.5–48 h). The gelatin concen-
tration in the solvent phase was kept constant (20 mg mL−1), 
the Poloxamer concentration in the non-solvent (acetone) 
was also kept constant at 3% w/v. The crosslinking incuba-
tion time was studied for two concentrations of DIC, 5 and 
15 mg mL−1.
Temperature of the Crosslinking Mixture: In addition, the nano-
suspension was also allowed to react with the crosslinker at 
different temperatures: room temperature, 30 °C, and 50 °C. 
The influence of reaction temperature was evaluated by investi-
gating the physicochemical attributes of the crosslinked GNPs.
3.3. Loading of Gelatin Nanoparticles with Model Protein Drug
As a proof of concept that a crosslinkable hydrophilic macro-
molecule can be incorporated and released, lysozyme was 
employed. The molecular structure of lysozyme possesses 
both primary amino groups as well as non-bonded carboxylic 
groups,[54] so maximum probability for chemical crosslinking 
caused by any crosslinker including DIC was given.
The GNPs were loaded with lysozyme following matrix 
incorporation methodology.[55] Briefly, 20 mg of gelatin were 
dissolved in water at 50 °C. Subsequently, lysozyme in different 
amounts was added to the gelatin solution. Afterward, the 
solvent phase containing gelatin and the payload were added 
to the anti-solvent phase (15 mL acetone containing Poloxamer 
188). Subsequently, the nanosuspension was crosslinked with 
347 µL DIC solution (taken from 69.16% w/v stock solution 
of DIC in acetone) and stirred for 20–24 h. Crosslinked GNPs 
were purified using TFF (Vivaflow 50 R, Sartorius Stedim Bio-
tech Ltd., Göttingen, Germany) using an ultra-filtration mem-
brane composed of modified regenerated cellulose with a pore 
size of 100 kDa. After purification, the loaded GNPs were char-
acterized for mean size (z-average), size distribution, and zeta 
potential.
3.4. Nanoparticle Characterization
3.4.1. Determination of Size and Surface Charge
The particle size and size distribution of DIC-crosslinked 
GNPs was measured after overnight crosslinking before and 
after purification. The size (z-average mean), size distribution, 
and zeta potential were measured in triplicates for each batch 
by DLS using the Zetasizer nano-ZS (Malvern instruments, 
Ltd., Malvern, UK). All samples were diluted tenfold in Milli-Q 
water before measurements. Formulations with a PDI below 
0.2 were assumed to be acceptable with respect to the size 
distribution.
3.4.2. Nanoparticle Morphology by Scanning Electron Microscopy
For SEM sample preparation, a silicon wafer was mounted on 
a metal hub using carbon adhesive tape. Then a drop of TFF-
purified nanosuspension was placed onto the silicon wafer. 
Subsequently, samples were dried by overnight evaporation 
under ambient conditions. Samples were then coated with a 
gold layer of ≈15 nm using sputter coater Q150 RES, (Quorum 
Technologies Ltd, East Grinstead, UK). SEM images were then 
obtained by SEM (EVO HD15 Carl Zeiss Microscopy GmbH, 
Jena, Germany).
3.5. Determination of Crosslinking Extent
For quantitative determination of percentage crosslinking 
degree of DIC-crosslinked GNPs, an established trinitro-ben-
zene sulfonic (TNBS) assay was employed.[47] Briefly, 10–12 mg 
lyophilized GNPs (both crosslinked and uncrosslinked) were 
dispersed in 1 mL of 4% sodium bicarbonate (NaHCO3) and 
1 mL of 0.5% TNBS. The mixture was then kept at 40 °C for 
4 h. Then, 3 mL of 6 N HCl was added and the mixture was 
autoclaved at 120 °C and 1.03–1.17 bar for 1 h.[47] The hydro-
lysate was diluted to 10 mL with deionized water and extracted 
with ethyl acetate to remove the unreacted TNBS. A 5 mL ali-
quot of the aqueous phase was diluted to 25 mL with water 
and the absorbance was recorded at λmax = 349 nm using a 
Perkin-Elmer Lambda35 UV-vis spectrophotometer (Rodgau, 
Germany) against a blank.
The blanks were prepared following the same procedure 
without addition of gelatin. The number of primary amino 
Macromol. Chem.  Phys. 2019, 220, 1900260
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groups was utilized as measure for crosslinking extent using 
Equation (1)
=
× − − b x
Moles of primary amino groups
Mass of gelatin in gram
2(Absorbance)(0.025L)
(1.46 10 L mole cm )( )( )4 1 1
 (1)
where 1.46 × 104 L mole−1 cm−1 is the molar absorptivity 
of TNB-lys, b is the path length in centimeters, and x is the 
sample weight in grams.
3.6. Quantification of Unreacted Crosslinker (DIC)
Gas chromatograms of unreacted crosslinker (DIC) in acetone 
were recorded with a gas chromatograph (GC) (Shimadzu 
GC-2010, Japan) coupled with a flame ionization detector 
(FID) (Shimadzu GC-2010, Japan). The analytical method 
proposed by Sigma-Aldrich was re-validated after necessary 
modifications. The supernatant was isolated by centrifuga-
tion of DIC-crosslinked GNPs at 24 000 × g for 20 min. Sub-
sequently, the supernatant was analyzed for unreacted DIC 
left in the nanosuspension using the validated method of gas 
chromatography.
3.7. Quantification of Crosslinking By-Product (Diisopropylurea)
The crosslinker DIC was after crosslinking of GNPs converted 
to its by-product DIU. Hence for the quantitative determination 
of DIU, 1H NMR spectra were recorded at 298 K in acetone-
d6 with a Bruker Avance 500 spectrometer (Bruker, BioSpin 
GmbH, Rheinstetten, Germany) equipped with a 5 mm BBO 
probe. The chemical shifts were reported in parts per mil-
lion (ppm) relative to the solvent peak at δH 2.05. All 1H NMR 
spectra must be recorded with a sufficient number of scans, 
typically NS = 128, to give an acceptable S/N, because the peaks 
of interest, the DIU methyl protons, were in the same range as 
those achieved for the carbon-13 satellites of the DIC methyl 
groups.
which can be determined by employing an already established 
method based on reversed-phase HPLC in gradient elution 
mode[56] with slight modifications. In brief, an Ultimate 3000 
series HPLC system, Rapid Speed (Thermo Fisher Scientific, 
Waltham, MA, USA) equipped with a quaternary pump and a 
Dionex Ultimate 3000 UV-vis detector with a LiChrospher 100 
RP-18e column (5 µm material, 4 × 125 mm, Merck KGaA, 
Darmstadt, Germany) was used. The column oven was heated 
up to 25 °C. The mobile phase consisted of two mobile phases, 
that is, mobile phase A (90% water and 10% acetonitrile acidi-
fied with 0.1% v/v trifluoroacetic acid) and B (90% acetonitrile 
and 10% Milli-Q water acidified with 0.1% v/v trifluoroacetic 
acid). The gradient started with 100% mobile phase A and 
decreased linearly up to 100% mobile phase B in 15 min. 
Afterwards, from 15 to 20 min, the column was equilibrated 
with 100% mobile phase A. The flow rate of mobile phase was 
adjusted to 0.8 mL min−1. For the detection and quantifica-
tion of lysozyme, the detector was set to 220 nm. The injec-
tion volume of the sample was 20 µL. For data analysis, the 
chromatography software Chromeleon 6.8 Chromatography 
Data System (Thermo Fisher Scientific, Waltham, MA, USA) 
was used, and the quantification was based on peak integra-
tion with the help of software thus recording the area under 
the chromatographic peak appearing at a retention time of 
8.9 min.
The lysozyme-loaded GNPs (both crosslinked and 
uncrosslinked) were subjected to washing with three times 
centrifugation (20 000 ×  g for 20 min) followed by re-dis-
persing in acetone (a non-solvent for lysozyme) after each 
centrifugation. The purified pellet of lysozyme-loaded 
GNPs was isolated. For the determination of encapsulation 
efficiency (EE%), 5 mg of uncrosslinked lysozyme-loaded 
nanoparticles were dissolved in 5 mL phosphate buffer saline 
(PBS) at pH 7.4 at room temperature (23 ± 2 °C). After dis-
solution of the nanoparticles, the samples were measured 
using gradient elution HPLC. A calibration curve was con-
structed with different concentrations of lysozyme in PBS 
at pH 7.4. The entrapment efficiency (EE%) was determined 
using Equation (2)
= ×Entrapment efficiency (%)
Weight of drug in nanoparticles/Weight of nanoparticles
Weight of durg used/Weight of gelatin used
100  (2)
3.8. Measurement of Drug Content and In Vitro Release
The model hydrophilic protein, that is, lysozyme was loaded 
into DIC-crosslinked GNPs in different drug/polymer ratios. 
The ratios ranged from 2.5% to 50%. The lysozyme was 
loaded in GNPs by adding the drug substance into the gelatin 
matrix solution prior to nanoparticles formation via nano-
precipitation. After particle formation they were stabilized 
by crosslinking with DIC. The loaded nanoparticles were 
physicochemically characterized including size, size distribu-
tion, and zeta potential. The lysozyme content in nanoparti-
cles was evaluated in terms of entrapment efficiency (EE%), 
For the determination of the in vitro release profile, a known 
amount of lysozyme-loaded GNPs after purification with ace-
tone was dispersed in PBS (pH 7.4) maintained at (37 ± 0.5) °C. 
The release medium was stirred at 400 rpm using a mechan-
ical shaker. At pre-determined time points, 1 mL supernatant 
was withdrawn and centrifuged at 20 000 × g for 20 min. The 
withdrawn aliquots were replaced with fresh release medium 
to maintain sink conditions. The pellets were re-dispersed and 
added to the original dissolution medium, keeping the par-
ticles concentration constant. The aliquots withdrawn from 
the supernatant were analyzed using RP-HPLC in order to 
quantify the fraction of lysozyme released at a particular time 
Macromol. Chem.  Phys. 2019, 220, 1900260
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point. Afterwards, the percentage cumulative mass of lysozyme 
released from crosslinked GNPs at its corresponding time 
points was calculated.
3.9. Determination of Biological Activity
This assay was based on the hydrolytic activity of lysozyme 
on its substrate M. lysodeikticus, a gram positive bacterium. 
For this assay, lyophilized crosslinked lysozyme-loaded GNPs 
(8 mg) were dispersed in 4 mL PBS (pH 7.4). After 24 h incu-
bation at 37 °C, 0.1 mL supernatant was withdrawn from the 
release medium and analyzed using the turbidimetric assay. 
For comparison, the release from GTA-crosslinked GNPs 
loaded with lysozyme was also measured. The quantification of 
enzymatic activity of lysozyme released from DIC-crosslinked 
GNPs was performed using standard protocols as provided 
by the supplier (Sigma-Aldrich). In brief, the substrate sus-
pension (0.015% w/v) was prepared after dissolving lyophi-
lized cells of M. lysodeikticus in PBS at pH 7.4. Then 2.5 mL 
of the substrate suspension was added to a suitable cuvette of 
1 cm path length. Afterwards, 0.1 mL sample from the super-
natant of lysozyme-loaded GNPs was added to the substrate 
suspension and carefully mixed. The decrease in absorption 
was recorded at 450 nm (ΔA450 nm) after 1 min using UV-vis 
spectrophotometer at 25 °C. For quantification, known con-
centrations of lysozyme were treated in the same way as 
described for the lysozyme-loaded GNPs to obtain a calibra-
tion curve (ΔA450nm per minute against known concentrations 
of lysozyme [µg/mL]). From this the masses of lysozyme could 
be determined which were then normalized to the highest 
activity for easier comparison.
4. Conclusion
This research work demonstrates a unique and novel 
approach of stabilization of GNPs with the aid of selective sur-
face crosslinking of the colloidal interface of GNPs. This was 
achieved by applying a hydrophobic zero-length crosslinker, 
that is, DIC. Crosslinking of GNPs produced, as a result of 
nanoprecipitation, GNPs with sizes of 200–300 nm. The sur-
face of DIC-crosslinked GNPs is positively charged at pH 
close to IEPs of gelatin. This shift in IEP is possibly due to 
the predominantly present protonated primary amino groups 
which are still uncrosslinked. The crosslinking degree was 
increased proportionally with increasing crosslinker concen-
tration until an equilibrium crosslinking degree was achieved 
(approximately 25–30%) which was not affected by increasing 
the crosslinker concentration and crosslinking time. The 
morphology of so-designed GNPs indicates spherical geom-
etry as confirmed by SEM analysis. There is a negligible 
crosslinking between gelatin matrix and lysozyme as evident 
from 90–100% release of lysozyme in the release medium. 
The activity of encapsulated lysozyme is mainly conserved 
after encapsulation which is in contrast to the crosslinking 
with GTA. In addition, the GTA-crosslinked GNPs loaded with 
lysozyme show only 30% release of lysozyme while a signifi-
cant fraction around 70% is believed to be covalently attached 
with the gelatin matrix. The surface-specific crosslinking can 
be inferred from the large released amount of lysozyme but 
also from the consumed amount of crosslinker showing a 
saturatable process. Therefore, it can be concluded that this 
surface crosslinked gelatin-based nano-delivery system pre-
sents an excellent opportunity for the delivery of lysozyme as a 
model drug for hydrophilic macromolecules such as peptide-
based bioactive compounds.
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